ÂÜÀòÂÒÂ×

Scott Platshon is an investment professional with a focus on the biotech sector, currently serving as an investor at EcoR1 Capital, LLC since October 2015. Additionally, Scott holds several board positions, including board member roles at Zymeworks Inc., Terremoto Biosciences, Ajax Therapeutics, and Kumquat Biosciences Inc., as well as a board observer role at BridgeBio Oncology Therapeutics and previously at PellePharm, Ashvattha Therapeutics, and Janux Therapeutics. Scott's experience includes serving as Chief Operating Officer at Panacea Acquisition Corporation I & II from July 2020 to May 2023. Educationally, Scott earned a Bachelor of Science in Bioengineering and Biomedical Engineering from Stanford University between 2009 and 2014, following studies at Menlo School from 2005 to 2009.